title: Toward postnatal reversal of ocular congenital malformations.
abstract: Aniridia is a panocular disorder that severely affects vision in early life. Most cases are caused by dominantly inherited mutations or deletions of the PAX6 gene, which encodes a transcription factor that is essential for the development of the eye and the central nervous system. In this issue of the JCI, Gregory-Evans and colleagues demonstrate that early postnatal topical administration of an ataluren-based formulation reverses congenital malformations in the postnatal mouse eye, providing evidence that manipulation of PAX6 after birth may lead to corrective tissue remodeling. These findings offer hope that ataluren administration could be a therapeutic paradigm applicable to some major congenital eye defects.
authors.forename: José-Alain
authors.initials: JA
authors.lastname: Sahel
authors.forename: Katia
authors.initials: K
authors.lastname: Marazova
mesh_terms: D000818:Animals; D015783:Aniridia / Q000628:therapy*; D005136:Eye Proteins / Q000235:genetics*; D005839:Gentamicins / Q000494:pharmacology*; D018398:Homeodomain Proteins / Q000235:genetics*; D010069:Oxadiazoles / Q000008:administration & dosage*; D000071841:PAX6 Transcription Factor; D051761:Paired Box Transcription Factors / Q000235:genetics*; D012097:Repressor Proteins / Q000235:genetics*
chemical_list: D005136:Eye Proteins; D005839:Gentamicins; D018398:Homeodomain Proteins; D010069:Oxadiazoles; D000071841:PAX6 Transcription Factor; D051761:Paired Box Transcription Factors; C000605732:Pax6 protein, mouse; D012097:Repressor Proteins; C515878:ataluren